Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC® protein degraders against validated and "undruggable" targets, the company has two clinical-stage programs: ARV-110 for the treatment of men with metastatic castrate-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer.
Company profile
Ticker
ARVN
Exchange
Website
CEO
John G. Houston
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ARVINAS HOLDING COMPANY, LLC, ARVINAS INC.
SEC CIK
Corporate docs
Subsidiaries
Arvinas Operations, Inc. • Arvinas Androgen Receptor, Inc. • Arvinas Estrogen Receptor, Inc. • Arvinas Winchester, Inc. ...
IRS number
472566120
ARVN stock data
Analyst ratings and price targets
Current price
Average target
$66.29
Low target
$49.00
High target
$81.00
Truist Securities
Maintains
$65.00
Wells Fargo
Downgraded
$49.00
Citigroup
Maintains
$72.00
Barclays
Maintains
$70.00
Piper Sandler
Maintains
$81.00
SVB Leerink
Maintains
$70.00
Morgan Stanley
Maintains
$57.00
Latest filings (excl ownership)
8-K
Regulation FD Disclosure
9 Jan 23
8-K
Arvinas Announces Changes to its Board of Directors
16 Dec 22
8-K
Regulation FD Disclosure
8 Dec 22
8-K
Regulation FD Disclosure
22 Nov 22
8-K
Regulation FD Disclosure
22 Nov 22
8-K
Regulation FD Disclosure
21 Nov 22
10-Q
2022 Q3
Quarterly report
9 Nov 22
8-K
Arvinas Reports Third Quarter 2022 Financial Results and Provides Corporate Update
9 Nov 22
8-K
Departure of Directors or Certain Officers
19 Aug 22
8-K
Arvinas Reports Second Quarter 2022 Financial Results and Provides Corporate Update
5 Aug 22
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 138.10 mm | 138.10 mm | 138.10 mm | 138.10 mm | 138.10 mm | 138.10 mm |
| Cash burn (monthly) | (no burn) | 10.18 mm | 22.40 mm | 20.83 mm | 22.20 mm | 19.83 mm |
| Cash used (since last report) | n/a | 40.91 mm | 90.07 mm | 83.74 mm | 89.27 mm | 79.75 mm |
| Cash remaining | n/a | 97.19 mm | 48.03 mm | 54.36 mm | 48.83 mm | 58.35 mm |
| Runway (months of cash) | n/a | 9.6 | 2.1 | 2.6 | 2.2 | 2.9 |
Institutional ownership, Q3 2022
98.5% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 174 |
| Opened positions | 28 |
| Closed positions | 22 |
| Increased positions | 59 |
| Reduced positions | 51 |
| 13F shares | Current |
|---|---|
| Total value | 2.55 bn |
| Total shares | 52.42 mm |
| Total puts | 74.80 k |
| Total calls | 333.70 k |
| Total put/call ratio | 0.2 |
| Largest owners | Shares | Value |
|---|---|---|
| FMR | 6.70 mm | $298.21 mm |
| Avidity Partners Management | 4.34 mm | $193.24 mm |
| Vanguard | 4.18 mm | $185.97 mm |
| BLK Blackrock | 3.71 mm | $164.90 mm |
| PFE Pfizer | 3.46 mm | $326.63 mm |
| EcoR1 Capital | 3.12 mm | $138.96 mm |
| BLVGF Bellevue | 2.19 mm | $97.47 mm |
| T. Rowe Price | 2.18 mm | $96.98 mm |
| JPM JPMorgan Chase & Co. | 2.09 mm | $93.07 mm |
| New Leaf Venture Partners, L.L.C. | 1.29 mm | $57.37 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 15 Dec 22 | Everett Cunningham | Common Stock Common Stock | Grant | Acquire A | No | No | 37.15 | 30,095 | 1.12 mm | 30,095 |
| 18 Aug 22 | John D Young | Stock Option Common Stock | Grant | Acquire A | No | No | 46.12 | 24,572 | 1.13 mm | 24,572 |
News
Truist Securities Maintains Buy on Arvinas, Lowers Price Target to $65
17 Jan 23
Where Arvinas Stands With Analysts
12 Jan 23
Guggenheim Downgrades Arvinas to Neutral
12 Jan 23
Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session
9 Jan 23
Stocks That Hit 52-Week Lows On Monday
9 Jan 23
Press releases
Arvinas to Present at 41st Annual J.P. Morgan Healthcare Conference
4 Jan 23
Arvinas Announces Changes to its Board of Directors
16 Dec 22
Arvinas Announces ARV-471 Achieves a Clinical Benefit Rate of 38% in Evaluable Patients and Continues to Show a Favorable Tolerability Profile in its Phase 2 Expansion Trial (VERITAC)
22 Nov 22